Publications
- Safety, immunogenicity and efficacy after switching from reference infliximab to biosimilar SB2 compared with continuing reference infliximab and SB2 in patients with rheumatoid arthritis: results of a randomised, double-blind, phase III transition study2018 | First Faculty of Medicine
- New inhibitor of interleukin 6 sarilumab in rheumatoid arthritis therapy2018 | First Faculty of Medicine
- A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy2017 | First Faculty of Medicine
- Long‑term effect and safety of secukinumab in the therapy of ankylosing spondylitis – a case study2023 | First Faculty of Medicine
- Biosimilar drugs: what a rheumatologist should know2023 | First Faculty of Medicine
- Diferenciální diagnostika horečky nejasného původu v revmatologické ambulanci2023 | First Faculty of Medicine
- Malé molekuly s velkými cíli - selektivní inhibice Janusovy kinázy 1 v terapii psoriatické artritidy2023 | First Faculty of Medicine
- IgA nefropatie: co by měl vědět lékař v praxi?2023 | First Faculty of Medicine
- The role od Janus kinase inhibitors in the therapy of psoriatic arthritis2023 | First Faculty of Medicine
- Chest pain2022 | First Faculty of Medicine, Second Faculty of Medicine, Central Library of Charles University
Loading network view...